BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of the BE MOBILE 1 study and the safety and efficacy findings.
The abstract ‘Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from BE MOBILE 1, a Phase 3, Multicentre, Randomised, Placebo‑Controlled Study.’ (Abstract number: POS0939) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What are the unmet needs in the treatment of patients with non-radiographic axial spondyloarthritis? (0:19)
- What is the rationale for the use of bimekizumab in the treatment of active non-radiographic axial spondyloarthritis? (1:20)
- What are the aims, design and eligibility criteria for the BE MOBILE 1 study? (2:27)
- What have been the efficacy findings at week 24? (3:10)
- What safety concerns are associated with the use of bimekizumab and what are the safety findings to date? (4:05)
Disclosures: Xenofon Baraliakos discloses consulting for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving payment or honoraria for lectures from: Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving grant/ research support from Abbvie, Novartis and MSD; serving on advisory boards for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving honoraria from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; participating in speaker’s bureaus for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
